divinevova.blogg.se

1. LINKDOC TECHNOLOGY DRIVER
2. LINKDOC TECHNOLOGY UPGRADE
3. LINKDOC TECHNOLOGY SOFTWARE
4. LINKDOC TECHNOLOGY PLUS
5. LINKDOC TECHNOLOGY SERIES

For any questions, please reach out to our editorial department.) However, we are not responsible for the accuracy of the information.

(China Money Network’s articles are curated and translated from credible Chinese media organizations with established brands, experienced editorial teams, and trustworthy journalism practices. Under the influence of factors such as the increase in the number of IoT connections, the slowdown of smartphone innovation, and the dual drive of hardware and scenario, the interactive models of electronic products are expected to usher in new iterations and updates, and the growth of consumer-level AIoT era is expected. CICC is optimistic about the Internet of Everything (IoE) to take over smart phones and start the next decade of consumer electronics innovation cycle. CICC: Internet of Everything opens a new decade, the growth of consumer-level AIoT is expectedĪccording to CICC’s research report, with the maturity of underlying technologies such as 5G and AI, they look forward to the gradual prosperity of next-generation applications represented by wearable devices, AR/VR, smart homes and smart cars. However, it will take several years to complete the equipment on half of the cars in use worldwide. Currently, in major markets such as China, Europe, Japan, and the United States, one-third of new cars have been equipped with ADAS functions.

LINKDOC TECHNOLOGY DRIVER

Global market research firm Canalys released the latest research report, pointing out that by the end of 2020, only 10% of every 1 billion vehicles in use worldwide are equipped with advanced driver assistance systems (ADAS). Canalys: Only 10% of every 1 billion cars in use are equipped with ADAS

LINKDOC TECHNOLOGY UPGRADE

After this round of financing, the company will continue to rely on AR/AI technologies such as space computing, AR cloud, natural interaction and AR smart hardware to strengthen and upgrade the AR platform HiAR Space and accelerate application of their products and services in vertical industries. The new round was led by CITIC PE, with participation from Jadex Capital, Yuanhui Capital and other existing investors such as V Star Capital, Xinxi Capital, Ondice Capital, MYEG, etc.

LINKDOC TECHNOLOGY SERIES

AR company HiScene completes a RMB270 million series C+ roundĪR technology company HiScene announced the completion of a RMB270 million series C+ round financing. LinkDoc plans to raise US$300 million before HK IPOĪlibaba-backed medical information platform LinkDoc Technology will start a new round of financing before Hong Kong IPO, and plans to raise US$300 million.

LINKDOC TECHNOLOGY SOFTWARE

Robovan’s design is based on Jiangling’s battery electric vehicle model, equipped with WeRide’s full-stack software and hardware solutions. WeRide launches first L4 self-driving cargo vanĬhinese autonomous driving technology developer WeRide launched its first L4-level self-driving cargo van yesterday and announced that it will work with Jiangling Motors, a major Chinese automobile manufacturer, and ZTO Express, a leading express delivery company in China, to drive mass production and the commercialization of the newly unveiled WeRide Robovan.

LINKDOC TECHNOLOGY PLUS

Medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.China Tech Digest: WeRide Launches First L4 Self-driving Cargo Van LinkDoc Plans To Raise US$300 Million Before HK IPO The study is a real-world study and the case records of patients with advanced non-small cell lung cancer who visited the research centers from January 2014 to December 2017 and met the inclusion criteria will be collected. Elemene, a chemotherapeutic isolated from the Chinese medicinal herb Rhizoma Zedoariae, has been shown to have a comprehensive anti-tumor effect and the potential effect on reversing drug resistance.

However, after a median of 8 to 13 months of disease control, patients ultimately progress due to acquired resistance of EGFR-TKIs. Gefitinib, Erlotinib, Icotinib, Afatinib showed efficacy superior to that of chemotherapy in the treatment of EGFR mutation positive advanced NSCLC, and lower rates of serious adverse events. Why Should I Register and Submit Results?Ībout 9.2%-45.8% of Chinese patients with Non-small cell lung cancer were positive for EGFR gene mutation.